|drug3022||Serology SARS-CoV2 Wiki||0.45|
|drug2952||Saliva sample Wiki||0.45|
|drug35||2019-nCoV IgG/IgM Rapid Test Cassette Wiki||0.45|
|drug2759||Recombinant Interferon Alfa-2b Wiki||0.45|
|drug2642||Psychological and Behaviour Change Support Wiki||0.45|
|drug2683||Querying the INSEE database Wiki||0.45|
|drug3581||Vitamin Super B-Complex Wiki||0.26|
|drug2113||Nasopharyngeal swab Wiki||0.17|
|D054058||Acute Coronary Syndrome NIH||0.22|
|D012327||RNA Virus Infections NIH||0.16|
|D003141||Communicable Diseases NIH||0.10|
There are 5 clinical trials
This registry will evaluate the impact of the COVID19 outbreak on Cardiac patients admitted in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France
This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX). Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology. The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".
Description: the patient clinical status at day 6 after hospital admission, defined as alive, or dead.Measure: Comparison of vital status Time: 6 days
Description: Evaluated by National Early Warning Score from 0 to 20, 20 being the worst score, with a high risk of death.Measure: Comparaison of severity Time: 6 days
Description: withMeasure: Comparaison of secondary effects (adverse events that needed disruption of treatment (anemia, tachycardia, osteoporosis) : secondary effects of coffee). Time: 6 days
The purpose of this study is to define seroprevalence of anti-SARS-CoV2 among children of Hospital Workers in APHP, particularly exposed population, according to parents' SARS-CoV2 serological status.
Description: Percentage of children with seropositive according to parents' SARS Cov2 serological statusMeasure: Seroprevalence of antibodies anti- SARS Cov2 in children of Hospital workers Time: at inclusion
The investigators hypothesize that detection of SARS-CoV2 on saliva samples will increase the performance of the screening program compared to the reference strategy (RT-PCR on a nasopharyngeal swab).
Description: RT-PCR on nasopharyngeal is considered as gold standardMeasure: Positivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virus Time: At diagnosis
Description: Number of samples tested in a day for each testMeasure: Practicability to samples Time: At diagnosis
Description: Quantity of premises required for each testMeasure: Practicability to premises Time: At diagnosis
Description: Feasibly Reading and interpretation For each testMeasure: Practicability to interpretation Time: At diagnosis
Description: Render times for each testMeasure: Practicability to render time Time: At diagnosis
Description: Research of IgG by ELISA and RDTMeasure: IgG Antibody detection in saliva Time: At diagnosis
Description: Research of IgM by ELISA and RDTMeasure: IgM Antibody detection in saliva Time: At diagnosis
Description: Research of IgA by ELISA and RDTMeasure: IgA Antibody detection in saliva Time: At diagnosis
Description: Evaluation by questionnaire of the patient tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions are about pain, discomfort, speed of performance)Measure: Patient tolerance of the salivary self-sampling Time: At diagnosis
Description: Evaluation by questionnaire of the operator tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions is about pain, discomfort, speed of performance)Measure: Operator tolerance of the salivary self-sampling Time: At diagnosis
Description: Including sampling, transport, technique (consumables, reagents, machine), human resourcesMeasure: Cost of each approach Time: At diagnosis
Mortality due to Covid-19 is much higher in the elderly. There are several reasons for the vulnerability of the elderly to the coronavirus: a less efficient immune system, underlying chronic conditions, less protected living conditions. They may also present a poor nutritional state and/or degraded metabolic reserves aggravating an underlying state of frailty. The prevalence of the risk of undernutrition in elderly patients with COVID-19 is high. The evolution of the nutritional status of people aged 70 years or older infected with SARS-Cov-2 is not yet well known. The prognosis of these patients could depend on their nutritional status at the time of the disease. In view of the lack of data, it would be interesting to compare the risk of mortality based on nutritional status in individuals with vs. those without COVID-19.
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports